Search details
1.
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
J Clin Oncol
; 41(9): 1714-1724, 2023 03 20.
Article
in English
| MEDLINE | ID: mdl-36669146
2.
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
J Thorac Oncol
; 18(9): 1165-1183, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37182602
3.
Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma.
JCI Insight
; 7(13)2022 07 08.
Article
in English
| MEDLINE | ID: mdl-35801592
4.
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.
Commun Biol
; 5(1): 373, 2022 04 19.
Article
in English
| MEDLINE | ID: mdl-35440675
5.
Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
Clin Cancer Res
; 27(5): 1463-1475, 2021 03 01.
Article
in English
| MEDLINE | ID: mdl-33355298
6.
Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1.
ACS Med Chem Lett
; 9(2): 103-108, 2018 Feb 08.
Article
in English
| MEDLINE | ID: mdl-29456796
7.
Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.
Commun Biol
; 5(1): 658, 2022 Jul 04.
Article
in English
| MEDLINE | ID: mdl-35787660
Results
1 -
7
de 7
1
Next >
>>